{"schema_version":"secwatch.filing_event.v1","accession":"0001737287-23-000074","form_type":"8-K","ticker":"ALLO","cik":"0001737287","company_name":"Allogene Therapeutics, Inc.","filed_at":"2023-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.045236+00:00","generated_at":"2026-06-12T14:14:13.532473+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Allogene reports Q2 2023 net loss of $78.0M; cash extends into 2H 2025","bullets":["Cash, equivalents, and investments $544.5M as of June 30, 2023; raised $87.9M via ATM in Q2.","Net loss $78.0M ($0.53/share) including $16.6M non-cash stock-based comp.","ALLO-501A Phase 2 ALPHA2 enrollment expected to complete 1H 2024; data readout by year-end 2024.","Long-term data from ALPHA/ALPHA2 trials showed complete response rates similar to approved autologous CAR T.","Cash runway now projected into 2H 2025; 2023 operating expense guidance ~$340M."],"urls":{"canonical":"https://secwatch.observer/filing/0001737287-23-000074","json":"https://secwatch.observer/filing/0001737287-23-000074.json","markdown":"https://secwatch.observer/filing/0001737287-23-000074.md","text":"https://secwatch.observer/filing/0001737287-23-000074.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737287/000173728723000074/0001737287-23-000074-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737287/000173728723000074/allo-20230802.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T14:14:13.532473+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c231e9645b26fe915f10a89620a5293118af9add","claim":"Allogene Therapeutics, Inc. reported financial results for the quarter ended June 30, 2023.","evidence_excerpt":"On August 2, 2023, Allogene Therapeutics, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended June 30, 2023 in the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1737287/000173728723000074/0001737287-23-000074-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}